L'intérêt à découvert pour iShares Bitcoin Trust donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de iShares Bitcoin Trust. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

iShares Bitcoin Trust (NASDAQ:IBIT), Rapport sur les intérêts à découvert

The Trust seeks to reflect such performance before payment of the Trusts expenses and liabilities. The Shares are intended to constitute a simple means of making an investment similar to an investment in bitcoin rather than by acquiring, holding and trading bitcoin directly on a peer-to-peer or other basis or via a digital asset platform. The Shares have been designed to remove the obstacles represented by the complexities and operational burdens involved in a direct investment in bitcoin, while at the same time having an intrinsic value that reflects, at any given time, the investment exposure to the bitcoin owned by the Trust at such time, less the Trusts expenses and liabilities. Although the Shares are not the exact equivalent of a direct investment in bitcoin, they provide investors with an alternative method of achieving investment exposure to bitcoin through the securities market, which may be more familiar to them.

iShares Bitcoin Trust

INTL BIOTECH TR PLC by International Biotechnology Trust Plc

IBITX Software Inc

<p><i>Complete cloud repository data security enables customers to securely leverage the cloud for business agility</i></p>
<p><strong>MICROSOFT IGNITE </strong>-<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.rubrik.com%2F&amp;esheet=54154601&amp;newsitemid=20241119672620&amp;lan=en-US&amp;anchor=Rubrik%2C+Inc.&amp;index=1&amp;md5=917b77bbd34636b9883d61268426f5a7">Rubrik, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>), the Zero Trust Data Security&#x2122; Company, today announces a new cyber resilience solution for <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fazure.microsoft.com%2Fen-us%2Fproducts%2Fstorage%2Fblobs&amp;esheet=54154601&amp;newsitemid=20241119672620&amp;lan=en-US&amp;anchor=Microsoft+Azure+Blob+Storage&amp;index=2&amp;md5=5965cd9378e23b0764d11ab358dea0fd">Microsoft Azure Blob Storage</a>. As organizations become increasingly dependent on the cloud, there is an inherent risk for security blind spots and vulnerable sensitive data. Rubrik brings cyber posture and cyber recovery to provide Microsoft Azure Blob Storage customers further visibility into their cloud data, enabling business agility and resilience.</p>
<p>Microsoft Azure Blob Storage provides secure object storage for cloud-native workloads, archives, data lakes, high-performance computing, and machine learning. Optimized for storing massive amounts of unstructured data, organizations across all industries use Microsoft Azure Blob Storage as a critical repository for sensitive business information, personal data, compliance records, and data powering artificial intelligence (AI) training models.</p>


News

MSFT

RBRK

Rubrik Delivers Cyber Resilience Solution For Microsoft Azure Blob Storage; Complete Cloud Repository Data Security Enables Customers To Securely Leverage The Cloud For Business Agility

<p><a href="https://www.bloomberg.com/news/articles/2024-11-19/airbus-ceo-says-year-end-delivery-goal-is-a-tough-journey">https://www.bloomberg.com/news/articles/2024-11-19/airbus-ceo-says-year-end-delivery-goal-is-a-tough-journey</a></p>
<p>Airbus SE Chief Executive Officer Guillaume Faury said that hitting a goal of 770 aircraft deliveries this year will be a sprint over the final weeks as the planemaker pushes to reach an already reduced target.</p>
<p>"I've seen too many years where we had the last minute," Faury said in an interview in Brussels, where he was attending a conference. "It's a tough journey and we're a bit late compared to what we were expecting. 770 is still our reference and we're working against that reference, and hopefully it's going to work."</p>


European Aeronautic Defence And Space Unsponsored

EADSY

"Airbus CEO Says Year-End Delivery Goal Is 'A Tough Journey'" - Bloomberg News

<p>On Monday,&nbsp;<strong>Eli Lilly And Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)&nbsp;announced Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a genetically inherited risk <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42047055/lillys-muvalaplin-lowered-lipoprotein-a-levels-in-adults-with-high-risk-for-cardiovascular-events-" rel="noreferrer noopener">factor for heart disease</a>.</p>
<p>In the U.S., about 20% of people, or approximately 63 million individuals, have high levels of Lp(a).</p>
<p>Elevated Lp(a) levels can double or even triple the risk of a heart attack and are associated with other cardiovascular issues.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/42039286/eli-lillys-zepbound-mounjaro-shows-cardiovascular-benefits-in-patients-with-obesity-related-heart-failure" rel="noreferrer noopener">Eli Lilly&#8217;s Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure</a></strong></p>
<p>The study demonstrated that muvalaplin significantly reduced elevated Lp(a) levels in adults, meeting its primary endpoint.</p>
<p>At the 12-week primary endpoint, muvalaplin (10 mg, 60 mg, and 240 mg) significantly reduced Lp(a) levels compared to placebo.</p>
<p>The placebo-adjusted reductions were up to 85.8% using an intact Lp(a) assay and up to 70.0% using an apo(a) assay.</p>
<ul>
<li>Specifically, the reductions were 47.6% (10 mg), 81.7% (60 mg) and 85.8% (240 mg) with the intact Lp(a) assay, and 40.4% (10 mg), 70.0% (60 mg) and 68.9% (240 mg) with the apo(a) assay.</li>
</ul>
<p>Muvalaplin also met secondary endpoints for all three tested doses (10 mg, 60 mg, and 240 mg).</p>
<ul>
<li>The three tested doses achieved statistical significance for Lp(a) thresholds, and the 60 mg and 240 mg doses also achieved statistical significance for apoB reductions.</li>
</ul>
<p>These data also demonstrated:</p>
<ul>
<li>Using the intact Lp(a) assay, the percentage of participants achieving normal Lp(a) levels of less than 125 nmol/L at week 12 was 64.2% (10 mg), 95.9% (60 mg), and 96.7% (240 mg), compared to 6.0% in the placebo group.</li>
<li>Using the apo(a) assay, 38.9% (10 mg), 81.9% (60 mg), and 77.4% (240 mg) of participants achieved an Lp (a) level of less than 125 nmol/L, compared to 3.6% in the placebo group.</li>
<li>ApoB levels were reduced at all doses, with placebo-adjusted reductions of 8.9% (10 mg), 13.1% (60 mg) and 16.1% (240 mg).</li>
</ul>
<p>Adverse events were similar in both the muvalaplin and placebo groups.</p>
<p><strong>Price Action:</strong> LLY stock is down 0.44% at $723.97&nbsp;at the last check on Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42060801/walmart-tops-q3-estimates-ecommerce-growth-shines-with-27-lifts-full-year-forecast" target="_blank" rel="noreferrer noopener">Walmart Q3 Earnings: Revenue Beat, eCommerce Growth Shines, Issues Bullish Outlook For FY25</a></strong></li>
</ul>
<p><em>Photo by Jonathan Weiss via Shutterstock</em></p>


Biotech

Large Cap

Health Care

General

Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%

<p><a href="https://www.bloomberg.com/news/articles/2024-11-19/microsoft-signs-ai-learning-deal-with-news-corp-s-harpercollins">https://www.bloomberg.com/news/articles/2024-11-19/microsoft-signs-ai-learning-deal-with-news-corp-s-harpercollins</a></p>
<p>&nbsp;</p>
<p><a href="https://www.bloomberg.com/quote/MSFT:US">Microsoft Corp.</a> reached a deal with <a href="https://www.bloomberg.com/quote/NWSA:US">News Corp.</a>'s HarperCollins that will allow the software company to use nonfiction titles from the book publisher to train its artificial intelligence models, according to a person familiar with the matter.</p>
<p>Microsoft wants the HarperCollins books for a model that it hasn't yet announced, according to the person, who asked not to be identified discussing plans that aren't public. The company isn't planning to use the content to generate new books without human authors, the person said. Microsoft declined to comment.</p>


NWSA

'Microsoft Signs AI-Learning Deal With News Corp's HarperCollins; Nonfiction Books Will Be Used For Training AI Models; AI Companies And Publishers Have Butted Heads In Lawsuits' - Bloomberg News

WIIM

Comfort Systems USA shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised its price target from $396 to $525.

SOFI

SoFi Technologies shares are trading higher after Mizuho maintained an Outperform rating on the stock and raised its price target from $14 to $16.

Red Hat Expands AI Innovation With RHEL AI on Microsoft Azure, Enabling Seamless Generative AI Deployment Across Hybrid Cloud Environments

<p><strong>Tryptamine Therapeutics Ltd</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TYPTF#OTC">TYPTF</a>) has <a href="https://www.proactiveinvestors.com.au/companies/news/1060916/tryptamine-therapeutics-will-advance-to-trp-8803-psilocin-phase-2-clinical-trials-1060916.html">announced</a> that its lead asset, <strong>TRP-8803</strong>, a <a href="https://www.benzinga.com/topic/psilocin">psilocin-based</a> IV infusion, will progress to <a href="https://www.benzinga.com/topic/psychedelics-research">Phase 2 clinical</a> trials following a successful Phase 1b study. <a href="https://www.benzinga.com/markets/cannabis/22/10/29142049/this-psychedelics-company-is-patenting-its-psilocin-and-psilocybin-delivery-route">TRP-8803</a> demonstrated significant advantages over oral <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a>, including rapid onset, precise control of the psychedelic state and the ability to halt treatment if adverse events occur, enhancing patient safety. </p>
<h3 class="wp-block-heading"><strong>Phase 1b Achievements</strong></h3>
<p>TRP-8803 was well-tolerated across all tested doses—low, mid and high—demonstrating its safety profile. The study identified optimal doses and infusion rates that maintained psilocin blood levels within the therapeutic range. Additionally, TRP-8803 achieved steady and controlled blood levels, outperforming oral psilocybin formulations in terms of consistency.</p>
<p>Participants experienced a rapid onset of the psychedelic state, much faster than the typical one- to two-hour delay with oral psilocybin. "To have achieved these positive results from our Phase 1b for TRP-8803 study so quickly has exceeded all expectations," said Tryptamine CEO <strong>Jason Carroll</strong>.</p>
<h3 class="wp-block-heading"><strong>Path To Phase 2</strong></h3>
<p>Armed with a robust proprietary dataset, Tryptamine is preparing to advance TRP-8803 to active patient studies. Phase 2 trials will target specific therapeutic indications, with planning already underway. Carroll highlighted the importance of these findings, stating, &#8220;Tryp has now established the strong foundations essential to advance our world-first trials for IV-infused psilocin to the highest standards of safety, quality and integrity.&#8221;</p>
<h3 class="wp-block-heading"><strong>TRP-8803: A Transformative Approach</strong></h3>
<p>TRP-8803 offers multiple advantages over traditional oral psilocybin. It provides faster onset, precise control over treatment duration and reversibility, enabling clinicians to halt therapy immediately if necessary. These features make the treatment safer and more commercially viable while reducing the overall duration of therapy. By promoting neuroplasticity, TRP-8803 aims to drive adaptive structural and functional changes in the brain, solidifying Tryptamine's position at the forefront of psychedelic medical innovation.</p>
<p><em>Cove imgage made with AI</em></p>


Cannabis

Psychedelics

TYPTF

Tryptamine Therapeutics Advances Psilocin-Based IV Infusion To Phase 2 Clinical Trials

DDOG

Datadog shares are trading higher. TD Cowen reiterated a Buy rating on the stock.

<ul>
<li><i>Kelly's acquisition of Children's Therapy Center (CTC) further expands growth opportunities in the high-margin, high-demand therapeutic services segment.</i></li>
<li><i>The integration of CTC into Kelly Education's Pediatric Therapy Services will bolster service delivery, offering Minnesota school districts access to comprehensive therapy solutions to address the increasing demand arising from student special education needs.</i></li>
<li><i>The addition of CTC brings increased scale to the current network of licensed therapists, enabling flexible practice in clinics or schools.</i><br /><br />&nbsp;</li>
</ul>
<p>TROY, Mich., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Today, <a href="https://www.kellyservices.com/">Kelly</a> (Nasdaq:&nbsp;KELYA, KELYB) announced that it has acquired <a href="https://childrenstherapyctr.com/">Children's Therapy Center (CTC)</a>. Specializing in occupational, physical, and speech therapy for children from birth to eighteen, CTC operates from its headquarters in Eagan, MN, with an additional office in Apple Valley, MN. This acquisition will integrate CTC into <a href="https://www.kellyeducation.com/">Kelly Education</a>'s <a href="https://www.mypts.com/">Pediatric Therapy Services (PTS)</a> portfolio. This provides opportunities for Minnesota school districts, including those who currently partner with <a href="https://www.teachersoncall.com/">Teachers On Call (TOC)</a>, a Kelly Education Company, to integrate PTS's related therapy services to meet the growing demand of student special education needs. The terms of the acquisition were not disclosed.</p>


KELYA

KELYB

Kelly Announces That It Has Acquired Children's Therapy Center; The Terms Of The Acquisition Were Not Disclosed

RDDT

Reddit shares are trading higher after Piper Sandler reiterated an Overweight rating on the stock and raised its price target from $115 to $150.

J-Long Group shares are trading lower after the company announced the receipt of a Nasdaq determination letter.

<p><strong>Incyte Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock is trading lower on Tuesday after the company announced that data from its Phase 2 study does not <a href="https://www.benzinga.com//node/42069374">support further development</a>. </p>
<p><strong>The Details</strong>: The company&#8217;s Phase 2 study evaluated MRGPRX4 in cholestatic pruritus, however, the data does not warrant further development.</p>
<p>In addition, Incyte announced that the company is pausing enrollment in its ongoing Phase 2 study of MRGPRX2 in chronic spontaneous urticaria. The decision was made after discovering some issues in early testing. </p>
<p>The company will work with the U.S. Food and Drug Administration to determine next steps.</p>
<p><strong>How To Buy Incyte Shares</strong></p>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Incyte's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p><strong>Related Link: <a href="https://www.benzinga.com/government/regulations/24/11/42045345/us-stocks-rebound-tesla-rallies-bitcoin-soars-above-92000-whats-driving-markets-monday">US Stocks Rebound, Tesla Rallies, Bitcoin Soars Above $92,000: What&#8217;s Driving Markets Monday?</a></strong></p>
<p><strong>INCY Price Action</strong>: At the time of writing, Incyte shares are trading 13.9% lower at $66.27, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><em>Image: Michal Jarmoluk from Pixabay</em></p>


Movers

INCY

What's Going On With Incyte Shares Tuesday?

<p>In the latest quarter, 21 analysts provided ratings for Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">14</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $98.62, along with a high estimate of $150.00 and a low estimate of $68.00. This upward trend is apparent, with the current average reflecting a 25.84% increase from the previous average price target of $78.37.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732039291_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Reddit among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Mark Shmulik</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Underperform</td>
<td>$85.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Alan Gould</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$118.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$116.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$99.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Alan Gould</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$89.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>John Colantuoni</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$87.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Josh Beck</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>John Colantuoni</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$77.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Reddit. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Reddit compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of Reddit's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RDDT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Reddit analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Reddit</h2>
<p>Reddit Inc is engaged in providing internet content. The company provides online services that include gaming, sports, business, crypto, television and others.</p>
<h3>Reddit: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Reddit's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>67.87%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> Reddit's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>8.57%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Reddit's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.54%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.41%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Reddit's debt-to-equity ratio is below the industry average at <strong>0.01</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Cracking The Code: Understanding Analyst Reviews For Reddit

Trading Ideas

CRWD

NDAQ

CNBC Halftime Report Final Trades: Nasdaq, D.R. Horton, CrowdStrike, iShares Core S&P Small-Cap ETF

<p>Analysts' ratings for Synchrony Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) over the last quarter vary from bullish to bearish, as provided by 13 analysts.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Synchrony Finl and provided 12-month price targets. The average target is $61.5, accompanied by a high estimate of $72.50 and a low estimate of $40.00. Witnessing a positive shift, the current average has risen by 9.66% from the previous average price target of $56.08.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732039265_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Synchrony Finl among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Scott</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$72.50</td>
<td>$64.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Moshe Orenbuch</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$62.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Mark Devries</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$59.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>John Hecht</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$62.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$40.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$68.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Mark Devries</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>David Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$59.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Synchrony Finl. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Synchrony Finl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>For valuable insights into Synchrony Finl's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SYF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Synchrony Finl analyst ratings.</strong></a></p>
<h2>Discovering Synchrony Finl: A Closer Look</h2>
<p>Synchrony Financial, originally a spinoff of GE Capital's retail financing business, is the largest provider of private-label credit cards in the United States by both outstanding receivables and purchasing volume. Synchrony partners with other firms to market its credit products in their physical stores as well as on their websites and mobile applications. Synchrony operates through three segments: retail card (private-label and co-branded general-purpose credit cards), payment solutions (promotional financing for large ticket purchases), and CareCredit (financing for elective healthcare procedures).</p>
<h3>Unraveling the Financial Story of Synchrony Finl</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Synchrony Finl's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>9.76%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Synchrony Finl's net margin excels beyond industry benchmarks, reaching <strong>20.14%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Synchrony Finl's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>5.28%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.64%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.06</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Critical Insights From Synchrony Finl Analyst Ratings: What You Need To Know

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>e.l.f. Beauty</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ELF, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for e.l.f. Beauty.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 50% bullish and 40%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $173,793, and 5 are calls, for a total amount of $435,620.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $110.0 and $270.0 for e.l.f. Beauty, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for e.l.f. Beauty's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of e.l.f. Beauty's whale trades within a strike price range from $110.0 to $270.0 in the last 30 days. </p>
<h3>e.l.f. Beauty Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732039266_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ELF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$1.8</td>
<td>$1.75</td>
<td>$1.75</td>
<td>$125.00</td>
<td>$180.3K</td>
<td align="right">762</td>
<td>1.6K</td>
</tr>
<tr>
<td>ELF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$2.15</td>
<td>$2.1</td>
<td>$2.1</td>
<td>$125.00</td>
<td>$113.1K</td>
<td align="right">762</td>
<td>542</td>
</tr>
<tr>
<td>ELF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$23.7</td>
<td>$21.7</td>
<td>$22.86</td>
<td>$125.00</td>
<td>$55.3K</td>
<td align="right">131</td>
<td>11</td>
</tr>
<tr>
<td>ELF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.9</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$270.00</td>
<td>$50.0K</td>
<td align="right">156</td>
<td>100</td>
</tr>
<tr>
<td>ELF</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$11.8</td>
<td>$11.7</td>
<td>$11.8</td>
<td>$125.00</td>
<td>$47.2K</td>
<td align="right">635</td>
<td>44</td>
</tr>
</tbody>
</table>
</p>
<h3>About e.l.f. Beauty</h3>
<p>e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan and cruelty-free cosmetics and skin care products. The Company's mission is to make the best of beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women which include eyeliner, mascara, false eyelashes, lipstick, the foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels. The products that the company sells are marketed under the e.l.f. Cosmetics, W3LL PEOPLE and Keys Soulcare brands. It carries out sales within the US and internationally, out of which maximum revenue is generated from the US.</p>
<p>Following our analysis of the options activities associated with e.l.f. Beauty, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is e.l.f. Beauty Standing Right Now?</h3>
<ul>
<li>With a volume of 965,299, the price of ELF is down -1.93% at $120.3. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<h3>Professional Analyst Ratings for e.l.f. Beauty</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $162.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from DA Davidson continues to hold a Buy rating for e.l.f. Beauty, targeting a price of $170.<br />
&#x2A; An analyst from Piper Sandler downgraded its action to Overweight with a price target of $165.<br />
&#x2A; An analyst from B. Riley Securities has decided to maintain their Buy rating on e.l.f. Beauty, which currently sits at a price target of $150.<br />
&#x2A; An analyst from JP Morgan persists with their Overweight rating on e.l.f. Beauty, maintaining a target price of $154.<br />
&#x2A; An analyst from Baird persists with their Outperform rating on e.l.f. Beauty, maintaining a target price of $175. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for e.l.f. Beauty with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

Check Out What Whales Are Doing With ELF

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Boeing</strong>.</p>
<p>Looking at options history for Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) we detected 46 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 54% of the investors opened trades with bullish expectations and 32% with bearish.</p>
<p>From the overall spotted trades, 20 are puts, for a total amount of $1,841,266 and 26, calls, for a total amount of $1,214,796.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $120.0 to $220.0 for Boeing over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Boeing's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Boeing's whale activity within a strike price range from $120.0 to $220.0 in the last 30 days. </p>
<h3>Boeing Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732039260_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$43.6</td>
<td>$38.5</td>
<td>$39.33</td>
<td>$170.00</td>
<td>$395.3K</td>
<td align="right">141</td>
<td align="right">102</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$39.35</td>
<td>$38.15</td>
<td>$39.35</td>
<td>$170.00</td>
<td>$161.3K</td>
<td align="right">141</td>
<td align="right">253</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$14.75</td>
<td>$14.05</td>
<td>$14.5</td>
<td>$120.00</td>
<td>$144.9K</td>
<td align="right">357</td>
<td align="right">207</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$14.45</td>
<td>$14.1</td>
<td>$14.45</td>
<td>$120.00</td>
<td>$144.5K</td>
<td align="right">357</td>
<td align="right">407</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$14.65</td>
<td>$14.2</td>
<td>$14.45</td>
<td>$120.00</td>
<td>$144.5K</td>
<td align="right">357</td>
<td align="right">307</td>
</tr>
</tbody>
</table>
</p>
<h3>About Boeing</h3>
<p>Boeing is a major aerospace and defense firm. It operates in three segments: commercial airplanes; defense, space, and security; and Global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with Lockheed, Northrop, and several other firms to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.</p>
<p>Having examined the options trading patterns of Boeing, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Boeing</h3>
<ul>
<li>With a volume of 4,215,868, the price of BA is up 0.33% at $144.35. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 71 days.</li>
</ul>
<h3>Professional Analyst Ratings for Boeing</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $204.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Benchmark downgraded its action to Buy with a price target of $250.<br />
&#x2A; An analyst from Susquehanna persists with their Positive rating on Boeing, maintaining a target price of $200.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Boeing, which currently sits at a price target of $170.<br />
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $200.<br />
&#x2A; An analyst from Baird persists with their Outperform rating on Boeing, maintaining a target price of $200. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Boeing, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Spotlight on Boeing: Analyzing the Surge in Options Activity

SNOW

Snowflake Partners With Microsoft To Launch Power Platform Connector, Enabling AI-Powered App Development And Enhanced Data Collaboration For Enterprises

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Qualcomm</strong>.</p>
<p>Looking at options history for Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) we detected 13 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and 46% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $2,092,331 and 6, calls, for a total amount of $217,041.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $150.0 to $230.0 for Qualcomm over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Qualcomm's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Qualcomm's substantial trades, within a strike price spectrum from $150.0 to $230.0 over the preceding 30 days.</p>
<h3>Qualcomm Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732039255_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$14.6</td>
<td>$14.5</td>
<td>$14.54</td>
<td>$165.00</td>
<td>$758.5K</td>
<td>119</td>
<td>1.0K</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$14.55</td>
<td>$14.45</td>
<td>$14.55</td>
<td>$165.00</td>
<td>$699.9K</td>
<td>119</td>
<td>1.0K</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$11.15</td>
<td>$10.8</td>
<td>$10.8</td>
<td>$150.00</td>
<td>$324.0K</td>
<td>2</td>
<td>300</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$17.35</td>
<td>$17.3</td>
<td>$17.3</td>
<td>$170.00</td>
<td>$197.2K</td>
<td>1.8K</td>
<td>114</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$2.38</td>
<td>$2.3</td>
<td>$2.42</td>
<td>$165.00</td>
<td>$55.9K</td>
<td>2.6K</td>
<td>659</td>
</tr>
</tbody>
</table>
</p>
<h3>About Qualcomm</h3>
<p>Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.</p>
<h3>Qualcomm's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,592,300, the price of QCOM is down by -0.28%, reaching $164.04.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 71 days from now.</li>
</ul>
<h3>What The Experts Say On Qualcomm</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $196.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Loop Capital downgraded its rating to Hold, setting a price target of $180.<br />
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on Qualcomm, which currently sits at a price target of $190.<br />
&#x2A; An analyst from Evercore ISI Group has decided to maintain their In-Line rating on Qualcomm, which currently sits at a price target of $199.<br />
&#x2A; Consistent in their evaluation, an analyst from Bernstein keeps a Outperform rating on Qualcomm with a target price of $215.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Qualcomm with a target price of $200. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Qualcomm, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


QCOM

Qualcomm Unusual Options Activity

U.S.-listed Bitcoin ETFs saw a significant shift on Thursday as investors pulled out $400.7 million—the third-largest outflow since their launch, a...

Bitcoin ETFs Face Massive Outflows Amid Market Correction

SA Charts: New Bitcoin peak shows how crypto market has changed since 2021

Beyond Bitcoin's Past Patterns: The Stars Are Aligning For Increased Adoption

Trump's Pre-Election Crypto Promises Could Spur Bitcoin To A Multi-Trillion Asset

Are Loose Financial Conditions Forcing Fed Caution On Rate Cuts?

The rally in spot Bitcoin ETFs is being fueled by a mix of factors, including the political landscape, with Trump's win sparking broader market opt...

Spot Bitcoin & Ethereum ETFs See Record Inflows as Market Hits New Highs

Weekly ETF Flows: SPY records inflows, bitcoin funds see large influx of capital

With Bitcoin Topping $90,000, Beware Of Crypto Copycats Like Dogecoin And MicroStrategy

A Georgia-based brokerage has settled allegations that it and its president developed and sold a trading strategy that they did not understand.

Georgia Broker-Dealer Learns Costly Lesson From FINRA

Options trading on spot Bitcoin ($BTC) exchange-traded funds (ETFs) could begin as soon as today (November 19), according to the Nasdaq ($NDAQ) exc...

Bitcoin ETF Options To Start Trading

ACTV

AFMC

AFSM

ARKB

ARKK

AVUV

BAPR

BITB

BITI

BRRR

BSQKZ

BTCO

BTCW

EZBC

FBTC

GBTC

HODL

HOOD

IBIT

IVOO

IVOV

MAGS

MSTR

SPLV

SPMD

SPMO

SPMV

SPSM

SPUS

SPUU

SPVM

SPVU

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SQEW

SQLV

SSPY

SVAL

SYLD

TMDV

TPHD

TPLC

TPSC

UAUG

UJAN

UMAR

UMAY

UOCT

UPRO

USMC

USMF

USVM

XLRE

Screenshot 2024-07-24 at 5.20.29 PM

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Lockheed Martin Looks To The Quantum Resistant Ledger For Secure Blockchain Communication

BlackRock's Bitcoin ETF Attracts $1 Billion In First Week of Trading

Crypto Stocks Rise Alongside Bitcoin

Bitcoin's Price Forecast To Reach $150,000 After Hitting All-Time High

BlackRock Holds Nearly 200,000 Bitcoin In ETF

Spot Bitcoin ETFs See First Outflows Of Capital

Bitcoin Drops 10 percent Post-Halving — Is It Still a Smart Buy in May 2024

BlackRock's Spot Bitcoin ETF Sees Biggest Inflow Since April

BlackRock Officially Becomes The Largest Spot Bitcoin ETF Custodian

BlackRock's Assets Surpass Record $10 Trillion Due To Bitcoin ETF

Spot Bitcoin ETF Options To Begin Trading

$BTC

$ETH

COIN

MARA

RIOT

TSX:FBTC

iShares Bitcoin Trust Beneficial Interest

Comments

iShares Bitcoin Trust

Intérêt court

iShares Bitcoin Trust (NASDAQ:IBIT), Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL